GET DAILY SIGNALSChemomab Therapeutics (CMMB): -5% Monthly Move as Scipher Merger Advances
Key Takeaways
- CMMB shares closed near $1.32 in early November 2026, roughly 5% below levels of about a month earlier, after a sharp late-September reset.
- The defining catalyst is the all-stock merger with Scipher Medicine, which pivots the combined company toward a biomarker-guided Phase 2 rheumatoid arthritis trial of nebokitug.
- Merger terms leave existing Chemomab holders with roughly 32% of the combined entity, a dilution factor that has weighed on investor sentiment.
- Nebokitug's Phase 2 SPRING data in primary sclerosing cholangitis (PSC) remain the core clinical asset, with FDA alignment on a single pivotal Phase 3 pathway.
- Chemomab generates no product revenue; a roughly $30 million private placement tied to the merger is expected to fund operations into the second half of 2028.
- For additional detail, explore Price Targets, Earnings, and Forecast pages on the company.
- Readers interested in automated strategies can explore Trending AI Robots.
Market Snapshot: CMMB's Recent Performance
Chemomab Therapeutics has traded in a volatile range through 2026, and the recent 30-day period reflects a relatively modest move of about negative 5%, far below the double-digit swings that defined earlier stretches of the year. Shares closed near $1.32 on November 6, 2026, within a 52-week range of $0.92 to $2.99, and remain positive on a year-to-date basis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. The modest month-over-month decline, however, masks a much steeper retreat that occurred in late September, when the stock fell from above $2.00 into the low-$1.00 range as details of the Scipher Medicine merger and its associated dilution reached the market. Since then, shares have stabilized near the lower end of their recent band, reflecting a market that is weighing clinical promise against the financial and structural terms of the pending combination.
Chemomab's Core Business and Pipeline
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company based in Tel Aviv-Yafo, Israel, focused on fibro-inflammatory and immune-fibrotic diseases with high unmet need. Its lead candidate, nebokitug (formerly CM-101), is a first-in-class humanized monoclonal antibody that neutralizes CCL24, a soluble protein implicated in fibrosis and inflammation. The company has reported positive Phase 2 SPRING trial results in primary sclerosing cholangitis, a rare liver disease, and has secured FDA and EMA Orphan Drug designation as well as FDA Fast Track designation, with regulatory alignment on a single pivotal Phase 3 study. Nebokitug is also being evaluated in systemic sclerosis. Because the company has no commercial-stage products or recurring revenue, its valuation is driven almost entirely by clinical data readouts, regulatory milestones, and its cash runway.
Key Recent Developments
The most significant development shaping Chemomab in the last 30 days is the continued progression of its merger with Scipher Medicine, a U.S.-based precision-medicine company. The definitive agreement, announced in July 2026, would combine Chemomab's nebokitug with Scipher's AI-driven diagnostic platforms to pursue a biomarker-selected Phase 2 rheumatoid arthritis trial, with topline data targeted for the first half of 2028. In late October and early November 2026, the companies filed an amended registration statement and proxy materials, and the SEC declared the Form S-4 effective, with a special meeting of Chemomab shareholders scheduled for December 4, 2026 to vote on the deal. From what I see, the terms carry meaningful dilution: existing Chemomab shareholders are expected to retain roughly 32% of the combined company, with Scipher holders receiving the remainder, and the deal includes a concurrent private placement of approximately $30 million from investors including Northpond Ventures and Khosla Ventures. The combination would trade under the Scipher Medicine name. Separately, Maxim Group analyst Michael Okunewitch has reiterated a Buy rating and a $5 price target, citing emerging nebokitug data and a cash position expected to fund operations into the first quarter of 2027, excluding Phase 3 costs. The pending shareholder vote and the risk that the merger may not close remain the central variables for the stock.
What to Watch in 2026 and Beyond
Investors following Chemomab into 2026 should monitor several near-term catalysts and structural risks. First is the December 4, 2026 shareholder vote on the Scipher Medicine merger, along with any changes to deal terms, financing commitments, or closing conditions. Second is the company's cash position and whether the private placement closes as planned, since the combined entity's runway into the second half of 2028 depends on that funding. On the clinical side, the Phase 2 SPRING data in PSC and the planned pivotal Phase 3 pathway remain the foundational value drivers, while the newly prioritized biomarker-guided rheumatoid arthritis program introduces fresh milestones, with Phase 2 data expected in 2028. Competitive dynamics in fibrosis and autoimmune indications, regulatory feedback, and the execution risk inherent in a reverse-merger-style restructuring all represent factors that could influence the stock's trajectory. As with any clinical-stage biotech, the absence of product revenue and the potential for further dilution remain key considerations. I’m watching this closely as the vote approaches.
Exploring Tickeron AI Tools
In my own research on volatile clinical-stage names, I often turn to Tickeron’s AI Trading Bots to review automated strategies that have shown recent strength. The platform offers a range of bots with different approaches and timeframes, which I find useful as a complement to fundamental analysis when evaluating potential catalysts like mergers or data readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CMMB in +7.32% Uptrend, rising for three consecutive days on November 06, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CMMB advanced for three days, in 195 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CMMB's RSI Indicator exited the oversold zone, 33 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CMMB as a result. In 61 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CMMB just turned positive on October 27, 2026. Looking at past instances where CMMB's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for CMMB crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CMMB broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CMMB entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.114) is normal, around the industry mean (3.498). P/E Ratio (-1.375) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. CMMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement